DACH Expansion Capitalize on Bencard Allergie's established presence in Germany and Austria to pursue distribution partnerships and contract manufacturing for prick-test diagnostics, OTC synbiotics, and perennial allergy therapies. Leverage the Allergy Therapeutics network to access an international sales footprint and accelerate regional market entry.

Molecular Profiling Expand diagnostic offerings in clinical settings by promoting prick-test kits and Allergomics-based molecular allergen characterization. This enables cross-selling with pharma partners and clinics and positions Bencard as a comprehensive allergy testing and management partner.

Innovation Partnerships Collaborate on advanced adjuvant technologies and virus-like particle platforms to co-develop next generation allergy therapies. This strengthens the value proposition for partners seeking differentiated immunotherapy capabilities.

Portfolio Synergy Leverage the broad product lines from diagnostics to consumer synbiotics to create bundled offerings for clinics, hospital pharmacies, and consumer channels. There are opportunities for joint marketing and integrated allergy care programs.

Strategic Growth A lean, research-driven organization with long-standing expertise can pursue manufacturing partnerships, toll manufacturing, and private-label opportunities within Europe, expanding market access and revenue potential under a collaborative framework.